Research progress and development strategies of antibody-oligonucleotide conjugates - PubMed
4 hours ago
- #antibody-oligonucleotide conjugate
- #gene therapy
- #drug delivery
- AOCs combine antibody delivery with oligonucleotide gene regulation for extrahepatic delivery.
- Unlike ADCs, AOCs use nucleic acid payloads for specific gene modulation with reduced off-target effects.
- AOC candidates for DMD have reached Phase III trials but face constraints like limited targets such as TfR1.
- AOC activity depends on antibody selection, linker design, and modification strategies.
- Target receptor endocytic efficiency is crucial for successful AOC therapeutic delivery.
- The study analyzes TfR1 antibody formats, linker structure-activity relationships, and nucleic acid modifications.
- Future AOC directions include bispecific antibodies, peptide conjugation, gene editing, and AI-driven approaches.